Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Gogoro Inc (GGR) vs Novartis AG (NVS) Price & Performance

Gogoro IncTrade
Novartis AGTrade

Price performance (Past 24H)

Key statistics

Gogoro Inc vs Novartis AG — how do they compare? Gogoro Inc trades at $2.51 (market cap $52.19M), while Novartis AG trades at $154.71 (market cap $295.37B). The key difference: Novartis AG is far larger — about 5659.5× Gogoro Inc's market cap, and Novartis AG pays a 3.07% dividend while Gogoro Inc pays none. Which is the better fit depends on your goals.

GGRNVS
Market Cap
$52.19M$295.37B
Sector
TechnologyHealth
52-Week High
$7.50$168.62
52-Week Low
$2.55$119.31
Enterprise Value
$354.63M$336.69B
Dividend Yield
3.07%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Gogoro Inc

GGR trades at $2.63, up 1.94% today, with a bearish technical signal from moving averages but oversold RSI readings. The company reported a net loss of $79.97 million on $281.48 million revenue in 2025, with negative margins and cash flow, though 2026 projections show improvement. Analyst consensus is entirely hold, reflecting caution amid ongoing losses.

Outlook remains challenging with persistent losses and negative cash flow, but low P/S and P/B ratios may attract value investors if operational improvements materialize. Key risks include execution on profitability, competitive pressures, and reliance on future growth initiatives to achieve sustained positive earnings.

Novartis AG

Novartis (NVS) trades at $152.41, down 2.79% today, with technical indicators showing neutral momentum near key support at $152. The company reported strong Q2 2026 earnings that beat expectations, driven by oncology drug performance, while maintaining a robust 22.5% net margin and $56.7B in revenue. Recent institutional buying activity and a predominantly Hold analyst consensus reflect cautious optimism amid patent expiration headwinds.

The outlook balances strong fundamentals and pipeline progress against generic competition risks. Investment appeal lies in dividend stability and new drug growth, though Entresto sales decline and U.S. pricing pressures require monitoring. The stock presents a defensive opportunity with moderate upside potential if newer therapies continue outperforming.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Gogoro Inc

Gogoro is a global technology leader in battery-swapping ecosystems for electric two-wheelers. It provides smart, sustainable urban mobility solutions and manages an extensive network of battery stations.

Read more on GGR

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

Read more on NVS